Quratis Inc. (KOSDAQ:348080)

Market Cap	97.75B +189.8%
Revenue (ttm)	2.46B +557.3%
Net Income	-29.67B
EPS	-412.00
Shares Out	105.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	319,891
Average Volume	403,735
Open	1,033.00
Previous Close	975.00
Day's Range	930.00 - 1,033.00
52-Week Range	556.00 - 2,095.00
Beta	-0.72
RSI	37.72
Earnings Date	n/a

About Quratis

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; QTP104, a next-generation mRNA vaccine; CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology; and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone. The company also offers drugs contract development and manufacturing services. Quratis Inc. was incorporated in 2016 and is based in Cheongju-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 348080

Financial Performance

In 2025, Quratis's revenue was 2.46 billion, an increase of 557.29% compared to the previous year's 373.80 million. Losses were -29.67 billion, 13.0% more than in 2024.